Point-of-care diagnostics of COVID-19 using isothermal amplification and CRISPR technology

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:239 publications

Grant number: Unknown

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2020
  • Known Financial Commitments (USD)

    $621,034.5
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    N/A

  • Research Location

    Canada
  • Lead Research Institution

    University of Alberta
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

This research addresses the urgent need of rapid point-of-care diagnostics of COVID-19. The collaborative research is conducted by a multi-disciplinary team of virologists, chemists, infectious disease specialists, front-line practitioners, and public health researchers from the University of Alberta, Canadian Food Inspection Agency, and Wuhan Institute of Virology (China). The immediate priority focuses on developing two complementary techniques to be performed on-site and in resource-limited settings, in support of rapid diagnosis of COVID-19. The diagnostic innovation takes advantage of the most recent advances in chemistry, molecular biology, genome technology, and nanotechnology. Chemical reactions required for efficient amplification and sensitive detection of the viral RNA take place in a single tube at a moderate temperature, simplifying the operation procedures. The specific reaction products are visible to the naked eyes, thus eliminating the need for any elaborate equipment. The first test reads color changes, with red color indicating negative and blue color indicating positive. Readout for the second test is color band on paper strips, similar to those of pregnancy tests, with two red bands indicating positive whereas a single control band indicating negative. The mid-term priority focuses on validating and evaluating the new diagnostic tests for field applications in the epidemic center of COVID-19. Our team members in Wuhan who currently perform the standard diagnostic tests will lead this effort. Once validated and approved, the new diagnostic tools will be used to support screening and diagnosis of COVID-19 at the community level. The mid-term objective also includes adapting the point-of-care diagnostics at other collaborating sites, e.g., Karachi (Pakistan) and Nairobi (Kenya). A longer-term priority of this research includes refining the new diagnostic tools to enable monitoring of mutational changes of the virus as it continues to evolve.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Development and Validation of the Intimate Partner Violence Workplace Disruptions Assessment (IPV-WDA).

Elucidating directed neural dynamics of scene construction across memory and imagination

Implementing a Novel Resident-Led Peer Support Program for Emergency Medicine Resident Physicians.

Cross-Activity Analysis of CRISPR/Cas9 Editing in Gene Families of <i>Solanum lycopersicum</i> Detected by Long-Read Sequencing.

Creating health systems citizens: enhanced professional identity formation through a para-curricular distinction track in health systems transformation and leadership.

A Comparison of Clinical Diagnostic Classification Criteria Used in Longitudinal Cohort Studies of the Alzheimer's Disease Continuum: A Systematic Review.

Identification and Characterization of a Rare Exon 22 Duplication in <i>CFTR</i> in Two Families.

Structural Rearrangement in Cyclic Cu(II) Pyridyltriazole Complexes: Oxidation of Dabco to Oxalate and CO<sub>2</sub> Conversion to Carbonate.

Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use.